One approach to addressing this problem is to investigate common harms encountered in ran domized controlled trials of antibiotic against placebo. This study design controls for disease related symptoms, allowing for better quantifica tion of antibioticrelated adverse effects.
The most common antibiotic used in primary care is amoxicillin, either alone or in combination with clavulanic acid. "Common harms" can be defined as those frequent enough to be observ able in the patient samples of most randomized trials and occurring during the recording of pri mary outcomes in such studies (with recognition that some of the adverse effects will occur later).
Accordingly, we systematically reviewed all published placebocontrolled randomized trials of amoxicillin or amoxicillin-clavulanic acid for any indication, with the rationale that the risks of druginduced harms are independent of the condition being treated. 4 
Methods

Design and registration
This systematic review with metaanalysis was regis tered with Prospero on May 11, 2012 (proto col available at www.crd.york.ac.uk/prospero/, regis tration number CRD42012002281).
Data sources
We searched MEDLINE (1946 to June week 4, 2013) , Embase (2010 to July 2013) and the Cochrane Central Register of Controlled Trials (to 2013, issue 7) using the Cochrane highly sen sitive search strategy for randomized trials (for the full search strategy, see Appendix 1, available at www.cmaj .ca/lookup/suppl/doi:10.1503 /cmaj.140848//DC1).
Study selection
We considered all randomized, participantblinded, placebocontrolled trials, in any language, with any population, in which amoxicillin or amoxicillinclavulanic acid was used to treat any condition. We excluded studies that involved coadministration of any drug other than acetaminophen (paracetamol).
Main outcome
Outcomes of interest were any reported adverse event, including nausea, vomiting, diarrhea, rash, candidiasis, itch and abnormal results on liver function tests.
Data extraction and synthesis
Two authors (M.G. and A.R.) independently screened the titles and abstracts of retrieved stud ies to identify those that appeared to meet the inclusion criteria. The full texts of these articles were similarly independently assessed for eligibil ity. Any disagreements were resolved by discus sion, and a third author (C.D.M.) arbitrated if ne cessary. The two reviewers used a standardized form to independently extract data from eligible studies, including event rates (with the intention totreat population as the denominator) and esti mates of bias. Discrepancies were resolved by dis cussion, and the same third author arbitrated if necessary. We examined the texts of included tri als for reported adverse events and checked regis tration information at trial registers for all included trials. The two reviewers independently undertook riskofbias assessment using Cochrane methods. 5 Disagreements were resolved by dis cussion, and the same third author arbitrated if
Records identified through database searching n = 1222
Additional records from reference lists of identified records n = 4
Records screened n = 730
Excluded n = 573
Full-text articles assessed for eligibility n = 157
Studies included in qualitative synthesis n = 45
Studies included in quantitative synthesis (meta-analysis) n = 25
Full-text articles excluded n = 112*
• Not an RCT n = 33
• Not a trial of antibiotic alone n = 78
• No control group without antibiotics n = 16
• Adverse effects provided only in aggregate for whole sample n = 1 • No full text available n = 1 *17 were excluded for more than one reason Excluded (duplicates) n = 496 necessary. We undertook sensitivity analyses based on patient age (adult or child), drug doses and durations of therapy, and we analyzed funnel plots to determine potential publication bias.
Statistical analyses
We used Peto odds ratios (ORs) to analyze the data (because of their paucity 5 ) and calculated 95% confidence intervals (CIs). We planned several subgroup analyses (see protocol at www.crd .york .ac.uk/prospero/). The numbers needed to harm (NNH) were estimated as follows: the OR for each harm was multiplied by the risk of harm with pla cebo (after converting this value to its odds) to derive the odds of harm in the antibiotic group; these odds were converted back to risks, and the absolute risk difference was then calculated. 6 
Results
Studies identified
We identified 730 studies (after removal of duplicates), of which 573 were classified as ineli gible on the basis of their titles or abstracts. Of the remaining 157 studies, 45 were included in the qualitative analysis and 25 in the quantita tive analysis (Figure 1) .
Description of studies
The trials were published from 1977 to 2013 ( Figure 2 ). The setting and reason for use of an antibiotic varied ( (Table 1) . Among the 25 trials that reported usable harms data, the mean number of types of harms reported was 2.7 (range 0-10). Most study reports gave minimal information about harm ascertainment. For 12 studies (27%) we could determine whether patients had been asked about specific harms; in 8 studies (18%) patients used a diary to record harms.
Funnel plots for the harms from diarrhea and rash were symmetric (Appendix 2, www.cmaj .ca /lookup/suppl/doi:10.1503/cmaj.140848//DC1).
Quality of studies
We found a low risk of bias in the reporting of antibiotic harms, although the principal focus of each trial was efficacy (Appendix 3, www.cmaj.ca /lookup /suppl/doi:10.1503/cmaj.140848//DC1). However, the reporting of such harms was poor: only 25 (56%) of the 45 studies reported harms in sufficient detail to allow metaanalysis of their data. The rate of studies reporting harms did not improve over time (Figure 2 ). Even studies that reported usable harms data rarely gave detailed information about how they were collected, and Research 
Treatment of respiratory or ENT infection
Burke et al. Note: amox-clav. acid = amoxicillin-clavulanic acid; ENT = ear, nose, throat; NA = not applicable; NR = harms data not reported; UTI = urinary tract infection; ? = not clear from trial report. *The most commonly prescribed dose if there was a loading dose. †At www.clinicaltrialsregister.eu, www.clinicaltrials.gov, www.controlled-trials.com or www.anzctr.org.au. ‡Harms data were reported, but the follow-up period was not specified and was likely variable. §Calculated only for studies with usable harms data ("Yes" in preceding column).
studies were sometimes unclear about whether all harms were reported (or, for example, whether they reported only those harms that led to with drawal of patients from the trial). Nine trials were registered, but registering harms among the sec ondary outcomes did not guarantee that harms would be reported (Table 1) , and registries did not provide any harms data that went unreported in the trials' primary publications. 41 Merenstein et al. 19 Meltzer et al. 18 Wald et al. 24 Jørgensen et al. 11 Burke et al. 7 Nduba et al. 20 Baecher et al. 31 Taylor et al. 23 Trehan et al. 51 Chantelau et al. 49 Sclafani et al. 29 Wald et al. 24 Marchant et al. 17 Kaiser et al. 12 Hoberman et al. 10 Winkel et al. 46 Gottfarb et al. 8 
Meta-analysis of reported harms
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157/1519 19 Shapiro et al. 37 Jørgensen et al. 11 Wald et al. 24 Trehan et al. 51 Burke et al. 7 Taylor et al. 23 Sclafani et al. 29 Hoberman et al. 10 Wald et al. 24 66/1842 Figure 3A ). There was high hetero geneity for all studies (I 2 = 68.8%), but not for amoxicillin-clavulanic acid alone (I 2 = 0%). The NNH for diarrhea was 10 (95% CI 6-17).
Candidiasis, reported in only 3 studies, was significantly caused by amoxicillin (OR 7.77, 95% CI 2.23-27.11,), with low heterogeneity ( Figure 3A) . The result was not significant for the subgroup of studies involving amoxicillin alone. The NNH for candidiasis was 27 (95% CI [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . In addition to explicit candidiasis, one trial reported rates of diaper rash of about 50% among infants treated with amoxicillin-clavulanic acid. 10 This rash was likely related to candidiasis as well. Analysis with inclusion of these data yielded the same OR value (data not shown).
Rashes, nausea and vomiting were not reported significantly more frequently with antibiotic than with placebo ( Figure 3B ). No trials reported itch ing, and only 1 trial reported abnormal results on liver function tests (which occurred in 2 placebo treated patients and 1 amoxicillintreated patient). 29 There were large variations in dose and dura tion of treatment among studies, and we explored this heterogeneity by subgroup analysis. Analyz ing studies that used common doses of amoxicil lin and those that used high doses, analyzing chil dren and adults separately, and analyzing studies with common duration of therapy (roughly 1-2 wk) and those with long courses of therapy yielded the same summary effect sizes for diar rhea (see Appendix 4, www.cmaj.ca /lookup /suppl/doi:10.1503/cmaj.140848//DC1). There were too few studies reporting other outcomes to undertake subgroup analyses.
Interpretation
In this metaanalysis of randomized trials, we found statistically significant results for just 2 harms: diarrhea from amoxicillin-clavulanic acid and candidiasis from amoxicillin with or without clavulanic acid.
Reported harms were fewer than we expected from clinical anecdotal experience and observationally derived data, which have primarily reported common harms as rashes (at rates of 5%-8% of those treated and even higher, up to 20%, among those with mono nucleosis treated with amoxicillin) and gastro intestinal disturbance. Some standard textbooks do not report candidiasis. 52, 53 At least 1 casecontrol study found a relative risk of 7 for thrush after therapy with amoxicillin or amoxicillinclavulanic acid. 54 Our reported rates of diarrhea (about 10% of courses of treatment) were similar to those in observational reports for amoxicillin-clavulanic acid 53 and similar to the rates from observa tional studies of amoxicillin (2%). 52 Standard texts 52, 53 report rash as common with these anti biotics, but we did not find a significant increase. However, the wide 95% CI for the OR means that metaanalysis did not rule out rash as a common harm.
Limitations
The most important limitation of this systematic review derives from the fact that every trial had a primary outcome relating to efficacy rather than harm. Many of the studies failed to report any harms, which led us to suspect that their authors simply did not collect such information or, if they did, failed to publish it. This problem was compounded by the lack of published protocols and registry information for most trials, which prevented analysis of planned measures, thus creating potential for selective reporting. In some of the studies that did report them, harms were probably recorded passively (that is, recording these outcomes only if volunteered by patients, rather than routinely asking all patients about them), which means underestimation of their rates was likely. 55 The low number of events also means that we had insufficient power to detect all but the most common harms. Each of these effects would lead to underestimation of harms.
One method of improving the power of a study like ours would be to undertake a network metaanalysis, including not only studies of anti biotic versus placebo, but also antibiotic versus other antibiotics (of which there are many), thereby exploiting differences among different antibiotics in their incidence of harms.
Nevertheless, these are currently the best esti mates we can obtain for harms of these com monly prescribed antibiotics.
Wellconducted, relatively large trials of amoxicillin and amoxicillin-clavulanic acid con tinue to be conducted, and better estimates may therefore be possible in the future, particularly with respect to the relationship between harms and dose, length of treatment and population. However, the availability of usable harms data from future studies will depend on adequate reporting by trial authors. We found that usable harms data were lacking in many of the studies included in our analysis, despite the existence of a CONSORT extension statement designed to encourage better reporting of harms. 56, 57 In our sample of trials, there was no discernible improvement in the reporting of harms for trials published in the decade since this extension statement was published, compared with trials published before.
Conclusions
Underreporting of harms in trials remains wide spread, 58 and until that problem is addressed, underreporting will flow to systematic reviews 59 and other evidence syntheses such as guidelines. An important consequence of underreporting of harms is misrepresentation of the balance of an intervention's benefits and harms, 59 but shared decisionmaking requires consideration of both these aspects. This systematic review has pro vided new information about common harms of amoxicillin and amoxicillin-clavulanic acid that can contribute to betterinformed discussions and decisions about the benefit-harm tradeoff for these antibiotics. However, it also highlights that the ability of clinicians and patients to make fully informed decisions about using amoxicillin and amoxicillin-clavulanic acid is hampered by poor measurement and reporting.
